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Background: A study to evaluate the impact of a combined intervention (in-class and on-line training courses, a
practicum and economic incentives) to improve anti-osteoporosis treatment and to improve recordkeeping for
specific information about osteoporosis.
Methods/design: A before/after study with a non-equivalent control group to evaluate the impact of the
interventions associated with participation in the ESOSVAL-R cohort study (intervention group) compared to a
group receiving no intervention (control group). The units of analysis are medical practices identified by a
Healthcare Position Code (HPC) referring to a specific medical position in primary care general medicine in a
Healthcare Department of the Region of Valencia, Spain. The subjects of the study are the 400 participating
“practices” (population assigned to health care professionals, doctors and/or nurses) selected by the Healthcare
Departments of the Valencia Healthcare Agency for participation as associate researchers in the ESOSVAL-R study
(intervention group), compared to 400 participating “practices” assigned to primary care professionals NOT selected
for participation as associate researchers in the ESOSVAL-R study, who are selected on the basis of their working in
the same Healthcare Centers as the practices receiving the interventions (control group). The study’s primary
endpoint is the appropriateness of treatment according by the Spanish National Health System guide (2010) and
the National Osteoporosis Foundation (NOF, 2008) and International Osteoporosis Foundation guidance (IOF, 2008).
The study will also evaluate a series of secondary and tertiary endpoints. The former are the suitability of treatment
and evaluation of the risk of fracture; and the latter are the volume of information registered in the electronic
clinical records, and the evaluation of risks and the suitability of treatment.
Background
Osteoporosis is a systemic disease of the skeleton char-
acterized by a loss in the bone’s resistance increasing
the risk of fracture. Resistance decreases when the
bone’s micro- and macro-structures deteriorate and
bone mass is lost [1]. Osteoporosis is highly prevalent
(1 in 3 women over the age of 50 in the Spanish setting
[2]) with an incidence that is rising as a result of the
greater life expectancy enjoyed by many of today’s socie-
ties. While osteoporosis is a silent disease, it has a very
important clinical impact because it involves a major
risk of bone fracture. The significant events associated
with osteoporosis are osteoporotic fractures, and their
associated morbidity and mortality. Osteoporotic frac-
tures most frequently occur in the thoracolumbar spine,
the hip and the wrist. Although the risk of fracture
increases in individuals with low bone mass, a previous
osteoporotic fracture is the best predictor for new ver-
tebral and hip fractures [3,4].
Osteoporotic fractures have important social and
healthcare repercussions. Mortality due to hip fracture
in hospitalized patients is between 5 and 8% and jumps
to 20-30% during the first year [5]; only one third of hip
fracture survivors recover their pre-fracture condition.
The presence and number of vertebral fractures has also
been related to a loss in quality of life [6,7] and greater
long-term mortality [8,9]. Vertebrae fractures, the most
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nosed and under-treated [2,10,11]. A wide range of
drugs are used to reduce the risk of osteoporotic
fracture, but there are no broadly accepted criteria to
estimate risk or to select patients for treatment. Interna-
tionally, one of the priorities of clinical research in the
field is to develop a set of simple clinical criteria that
can be used in daily practice to help doctors decide
whom to treat, and when to initiate treatment.
The Valencia Health Agency, the public healthcare
network providing healthcare close to 95% of the inhabi-
tants of the Region of Valencia, Spain, has been imple-
menting in the last years an electronic clinical record
system, called ABUCASIS. For practical purposes, ABU-
CASIS becomes a population-based electronic database
enabling the monitoring of the most relevant clinical
and therapeutic data and allowing longitudinal studies
on the 5 million people attending the Valencia Health
Agency healthcare centres.
The Valencia osteoporosis study ESOSVAL [12] is one
of the cornerstones of the 2nd Plan for the Prevention
and Follow-Up on Osteoporosis in the Region of Valen-
cia that has been initiated by the Regional Ministry of
Health [13]. Its aims are to improve osteoporosis care
and reduce the risk of fracture by providing clinical
training for professionals,m o d i f y i n gt h eA B U C A S I S
clinical records system with specific changes related to
osteoporosis prevention and management. The Plan will
also promote research that can be applied in routine
clinical practice. The ESOSVAL project involves the
training of 800 primary care doctors and nurses who
participate in the ESOSVAL-Risk (ESOSVAL-R) study
[12]. These professionals will use the modified ABUCA-
SIS computerized clinical records to follow-up 14,500
patients during 7-10 years. The main objective of the
ESOSVAL-R project is to develop a scale to predict
the risk of osteoporotic fracture in any location, and in
the hip, to serve as the base to establish criteria for the
efficient treatment of osteoporosis [12].
The professionals who participate in the ESOSVAL-R
project will engage in a multifaceted intervention - the
ESOSVAL Formation (ESOSVAL-F) study - that includes
training, practical activities and some economic incen-
tives. At the start of the project, the participants receive
four hours of practical training on collecting and record-
ing information about osteoporosis in ABUCASIS. Then
they recruit and follow-up on the patients who will take
part in the ESOSVAL-R study. This involves collecting
information relevant to the study from the clinical
records of 18 participating patients under their care. Par-
ticipation in the study has, furthermore, been included as
an “indicator” to obtain points towards the financial
incentives included in the Valencia Health Agency’s
Management Contract. Additionally, all participating
professional are engaged in an on-line training course on
osteoporosis prepared by recognized experts in the field.
The intervention will conclude with further classroom
reinforcement in the first quarter of 2011.
T h em a i no b j e c t i v eo ft h eE S O S V A L - Fs t u d yi st o
evaluate the impact of this multifaceted intervention on
improvements in the appropriateness of anti-osteoporo-
sis treatment, and improvements in recordkeeping of
the information that is specifically related to osteoporo-
sis and osteoporotic fractures in the ABUCASIS electro-
nic clinical records, comparing the results of the
medical professionals participating in the ESOSVAL-R
study (Intervention Group) with those clinicians who
are not participating in the project (Control Group).
Methods/Design
Main Objective
To evaluate the impact of a multifaceted intervention
on the improvement of the appropriateness of anti-
osteoporosis treatment and on the inclusion of specifically
related to osteoporosis information in the electronic
clinical records.
Specific objectives
1. To describe the appropriateness of treatments and the
volume of specific information related to osteoporosis at
the beginning of intervention (baseline situation).
2. To analyze any possible baseline differences in
managing osteoporosis between the Intervention and
the control group.
3. To evaluate the impact of the multifaceted interven-
tion, taking into account any differences between con-
trol and intervention groups in appropriateness of
treatment and in the quality and volume of the informa-
tion on osteoporosis registered once the intervention
has finished.
4. To analyze the degree of improvement in the
appropriateness of treatment and in the thoroughness of
recordkeeping throughout the intervention period, sepa-
rately for both groups, and analyze any differences in
these changes by comparing the values collected after
the interventions with the baseline values for both
groups.
Design
Before/after study with a non-equivalent control group
to evaluate the impact of the interventions associated
with participation in the ESOSVAL-Risk cohort study.
To summarize very briefly, the ESOSVAL-R study is
being conducted with aprox. 14,500 men and women
recruited from all over the Region of Valencia into 400
practices under the care of participating primary care
doctors and nurses [12]. These persons will be followed
for 7 to 10 years to evaluate various objectives related to
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low-up of these patients, the ESOVAL-R project imple-
mented various changes to the system used to register
information in the patients’ clinical records throughout
the entirety of the Valencia Healthcare Agency, and will
conduct training activities with the participating health-
care professionals, some of which are associated with
incentives of various type. The impact of these interven-
t i o n si sw h a ti sb e i n ge v a l u a t e di nt h ec u r r e n tE S O S -
VAL-F project.
Setting
R e g i o no fV a l e n c i a ,S p a i n ,a n d ,s p e c i f i c a l l y ,t h ep r i m a r y
care network depending from the Valencia Health
Agency. In the Region of Valencia, as in Spanish
National Health System, coverage is practically universal,
with 97% of the population served by the Valencia
HealthCare Agency administered by the Regional Gov-
ernment. The Agency is structured in 24 main Health
Districts (where a geographical area with about 200,000
people is served by one public hospital), and 234 geogra-
phically delimited Basic Health Areas, with 5,000-25,000
people served by a Primary Healthcare Centre. Other
noteworthy features of the Valencia HealthCare System
are the cost-free status of care, hospital and primary
care funding by means of government budgets and the
fact that doctors, who enjoy a civil servant-like status,
are paid by salary with discrete economic incentives
linked to performance in a pool of organizational and
clinical indicators defined annually in the so-called
“Health Agency’s Management Contract”.
Population and sample
The units of analysis of the ESOSVAL-F are the medical
practices (the people registered with each general prac-
tice doctor) of the Healthcare Departments of the
Region of Valencia. The intervention is directed to the
doctors and/or nurses attending these practices. Inclu-
sion criteria were the following:
- Intervention group: was integrated by Medical
Practices participating in the ESOSVAL-R study. To
be selected the corresponding professional should
occupy a titular position as general practice doctor o
nurse (excluding out-of-hours, temporal substitutes
and emergency professionals) with anticipated conti-
nuity at least three months after ESOSVAL-R
recruitment, have an operating email address and a
computer with internet access, and agree for partici-
pation in the study.
- Control Group was integrated for medical practices
NOT selected for participation in the ESOSVAL-R
study. These practices were selected on the basis of
their belonging to one practice of the intervention
group. If possible, we choose the same Healthcare
Centre and a practice with similar timetable and size
of registered patients. When this was not possible,
another one belonging to the same Department was
selected.
The size of the sample in the Intervention Group (n =
400 general practices) was predetermined by the objec-
tives of the ESOSVAL-R study [12]. The same number
of practices was recruited for the Control Group (n =
400). Assuming a type I error of 0.05 (two tailed-tests)
and a power of 0.90, 400 units in each branch of the
study (ratio = 1 between groups) provides sufficient
power to be able to detect differences in the study’s
main variable.
Intervention
Given the characteristics of the ESOSVAL project linked
to the Regional’s Plan of Osteoporosis, both the Inter-
vention and the Control Group will receive some form
of intervention aimed at improving care. The Control
Group will benefit from the improvements introduced
by the ESOSVAL project in the ABUCASIS Electronic
Clinical Records system, since they affect all the system’s
users, the doctors and nurses providing healthcare,
including those in the Control Groups. These improve-
ments consist in the incorporation of a new follow-up
sheet for patients with osteoporosis or risk factors for
osteoporosis, and a series of tables, scales and variables
that can be monitored to improve the care and follow-
up of these patients. The implementation of this change
in the patients’ clinical records will be done through the
usual training process used by the Valencia Healthcare
Agency to introduce any change in recordkeeping (an
informational session, and the option to have any indivi-
dual questions answered).
The intervention group, and apart from the above
mentioned changes to the recordkeeping system, receive
a multifaceted intervention: 1) The participating clini-
cians took a four-hour classroom course in the last
quarter of 2009, held in each Department; 2) Next, they
participated in recruiting and following-up on patients
for the ESOSVAL-R study. This requires the healthcare
providers to include relevant information in the clinical
records of 18 patients, and involves a hands-on practi-
cum in obtaining information about osteoporosis and its
incorporation into the clinical records; 3) participation
in the study has been included as an “indicator” towards
gaining points in the Valencia Health Agency’s Manage-
ment Contract, that will lead to economic incentives; 4)
An on-line course on osteoporosis will be given during
the first, third and fourth quarters of 2010. It is orga-
nized in modules prepared by recognized national
experts; 5) During the first quarter of 2011, after all the
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on-line course, another classroom course will be given
to reinforce training and to divulge the results collected
so far during the intervention (Table 1). The courses
will be given to the doctors and nurses in the Region’s
Healthcare Departments who volunteer for participation
in the project and who work with the medical practices
selected.
Outcomes
The expected short-term results of the intervention are
to improve the recordkeeping of information about
osteoporosis and osteoporotic fracture and to improve
appropriateness of treatment and the request of diag-
nostic tests. The expected long term results of the inter-
vention are to reduce the incidence of osteoporotic
fracture. The evaluation currently being conducted in
this study intends to examine only the expected short
term results. The evaluation of the long-term results
will require from seven to ten years of follow-up. In this
context, results will be measured as:
Main endpoint
Appropriateness of treatment according by the Spanish
National Health System guide (2010) [14] and the
National Osteoporosis Foundation (NOF, 2008) [15] and
International Osteoporosis Foundation guidance (IOF,
2008) [16].
Secondary endpoints
1) Percentage of people ≥70 years diagnosed with osteo-
porosis and/or osteoporotic fracture treated with alen-
dronate, risendronate, ibandronate or strontium ranelate,
compared to all people ≥70 years in the practice. These
values will also be analyzed with a breakdown for gender;
2) Percentage of patients ≥50 years NOT diagnosed with
osteoporosis nor osteoporotic fracture treated with anti-
osteoporotic drugs, compared to the total population ≥50
years in the practice, total and by gender; 3) Percentage
of patients ≥50 and ≤ 65 years with a diagnosis of osteo-
porosis/osteopenia without osteoporotic fracture, receiv-
ing treatment with anti-osteoporotic drugs; 4) Percentage
of patients ≥50 years in treatment with calcium and/or
vitamin D, with a diagnosis of osteoporosis and/or osteo-
porotic fracture; 5) Percentage of patients ≥70 years in
treatment with raloxifene, teriparatide, PTH or calcito-
nin, with a diagnosis of osteoporosis and/or osteoporotic
fracture; 6) Percentage of patients ≥70 years in treatment
with raloxifene, teriparatide, PTH or calcitonin, with no
diagnosis of osteoporosis or osteoporotic fracture. 7) Per-
centage of patients ≥50 diagnosed of osteoporotic frac-
ture (vertebra, wrist, proximal humerus or other specific
and non-specific sites), compared to the total population
of patients ≥50 years in the practice, total, by type of frac-
ture, age group and gender; 8) Percentage of patients ≥50
years who diagnosed of osteoporosis/osteopenia (OMS
criteria), compared to the total population of patients
≥50 years in the practice, total, by age group and by
gender.
Tertiary endpoints
1) Percentage of patients ≥70 years for whom the “evalua-
tion of the risk of fall” form has been filled in, compared
to the total population ≥70 years in the respective prac-
tices, total and by gender; 2) Percentage of patients ≥50
years with a diagnosis of a sedentary life-style, compared
to the total population of patients ≥50 year in the practice,
total and by gender; 3) Percentage of women ≥50 years
with a diagnosis of early menopause, compared to the
total women of patients ≥50 years in the practice; 4) Per-
centage of patients ≥50 years for whom the “Evaluation for
family history of osteoporotic fractures” form has been
filled in, compared to the total population of patients ≥ 50
years in the practice; 5) Percentage of patients ≥ 50 years
for whom the “Evaluation for calcium intake” form has
been filled in; 6) Percentage of patients ≥50 years for
whom the evaluation for smoking has been filled in; 7)
Percentage of patients ≥50 years for whom the evaluation
Table 1 ESOSVAL-Formation Project chronogram
Year 2009 2010 2011
Quarter 123 41 2 3412
Design of the Training Plan ►► ► ▐
Design of the Research Project: ESOSVAL-F ►▐
Presentation to Ethical Committee ►▐
Changes to the electronic clinical history system to improve recordkeeping on osteoporosis ►► ► ▐
In-class training courses in the Healthcare Departments ►▐ ►▐
“On-line” training ►► ► ▐
Statistical analysis ►► ▐
Issue of report on results ►►
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patients ≥ 50 years for whom the evaluation of body mass
index has been filled in.
Others variables and definitions
Associated with the practice
Healthcare Center, Basic Healthcare Zone, Health
Department, timetable (for appointments with patients),
size (number of patients assigned to the professional).
Associated with the doctor in charge of the practice
Age, sex, training (whether she/he had their Family Phy-
sician certificate after an nationally accredited 3-4 years
residency program), contractual conditions, number of
years practicing in primary care, number of years occu-
pying the current position.
Associated with the patients in each practice
age, sex, body mass index, smoker status, drinker status,
physical activity habits, antecedents of first degree family
member with hip fracture, calcium intake, non-treated
hypogonadism, rheumatoid arthritis, other diseases
affecting the bones excluding hypogonadism, use of oral
glucocorticoids, use of other drugs affecting the bones
(excluding glucocorticoids), previous osteoporotic frac-
ture, risk of fall, prolonged immobilization, osteoporosis
of the lumbar spine assessed by DXA (T score for L2-
L4), osteoporosis of the hip assessed by DXA for the
whole hip or femur neck (T score), anti-osteoporotic
treatment.
Data sources
All of the data pertaining to the patients in the medical
practice will be taken from the ABUCASIS Electronic
Clinical Records system. The data concerning the prac-
tice and the doctors and nurses will be supplied by the
Valencia Healthcare Agency.
Development of the study
The study will be undertaken in accordance with usual
conditions of clinical practice and good clinical practice.
As per the working plan detailed below, changes in the
clinical records come into effect in the computer system
during the last quarter of 2009, simultaneously with the
in-class training courses. Further training will be pro-
vided during 2010, and the information collected during
the first quarter of 2011 will be used to compare the
results of the Intervention and Control Groups.
Statistical Analysis
1) Once the patients in all of the practices have been
recruited, and at the beginning of the training period,
the baseline information for both the IG and the CG
will be analyzed. Information about the demographic
features of the practices receiving healthcare and about
the various results measured will be recorded, using the
necessary parameters for each variable (means, propor-
tions) with their corresponding 95% confidence intervals
(CI95%). Additionally, any differences between the two
groups will be analyzed using appropriate tests to mea-
sure differences in proportions. 2) One year after the
start of the study, and coinciding with the completion of
the on-line training, the parameters used in the baseline
study will be re-evaluated to detect any differences in
results between the IG and the CG. Additionally, paired
tests will be used to analyze any before/after differences
in the IG and the CG, and any improvements made in
the groups will be compared with tests of differences
between proportions. Controls will be used for the self-
correlation expected between the results of patients
under a single doctor’s care. All of the statistical ana-
lyses will be done with the STATA program.
Ethical aspects
The study will be conducted according to the interna-
tional standards for epidemiological studies, as estab-
lished in the International Guideline for Ethical Review
of Epidemiological Studies (Council for the International
Organizations of Medical Sciences, Geneva, 1991) and by
the Spanish Society of Epidemiology on the review of the
ethical aspects of epidemiological research. The study has
been approved by the Committee for Ethics and Clinical
Essays of the Centro Superior de Investigación en Salud
Pública (Center for Public Health Research).
The ESOSVAL-F study is being conducted under the
usual conditions of clinical practice; beyond the training
interventions and those designed to help healthcare pro-
fessionals improve their clinical practice, the study does
not provide the participating patients with intervention
i na n yf o r mt h a ti sd i f f e r e nt from what is provided to
non-participating patients. The participation of the doc-
tors and nurses in the ESOSVAL-F study does not
involve providing the patients with preventive proce-
dures, or additional diagnostic or therapeutic measures,
beyond what their doctors and nurses deem appropriate.
Therefore, the participation of the doctors and nurses in
the study does not include any added risk for the
patients receiving their care. All of the interventions
directed towards improving healthcare are part of
improvement strategies being deployed throughout the
healthcare system in its entirety (changes in the Clinical
Records), or represent training interventions provided
exclusively for healthcare staff (doctors and nurses).
The treatment of personal information in the ESOS-
VAL-F study complies with Spanish Organic Law 15/
1999 and Law 41/2002 of November 14, the instruments
which regulate patient autonomy and rights and obliga-
tions concerning clinical information and documenta-
tion. Article 16.3 of Law 42/2000 establishes that “access
to clinical records for legal, epidemiological, public
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all data identifying the patients from all medical or
health-related data, in such a way that, as a general rule,
the patient’s anonymity is preserved, unless the patient
himself has given consent to not separating these [types
of] data.” All patient data obtained from the ABUCASIS
system will be held anonymously and separately, and
will solely be linked to a key that will exclusively be
used in the context of the system, in such a way that
only authorized personnel from the ABUCASIS office
(and never members of the research team) will be able
to associate such data to an identified or identifiable per-
son. In no circumstances will members of the research
team have access to data identifying the patients.
Discussion
A series of limitations are foreseen in connection with
this study:
Selection bias
While criteria for inclusion into the intervention group
include having volunteered for participation in the
ESOSVAL-R study, the control group is composed for
professionals who have not made such a request. This
aspect suggests there may be differences in the baseline
characteristics of the two groups, maybe with influence
in the study endpoints. Strategies to minimize this risk
include selecting for participation in both groups profes-
sionals from the same Healthcare Centers and with
similar patient assignations. Nevertheless, as occurs in
all studies with non-equivalent control groups, the selec-
tion bias cannot be entirely discarded.
Information bias
These may occur when a clinical record is missing, or
when information is not registered uniformly in the
Electronic Clinical Record. The main problem here is
that measuring the appropriateness of treatment and the
quality of the information recorded about the patients
depends on the amount of information registered in the
system, and this volume may differ between the control
and the intervention group. Although the volume of
information itself is being used as measurable endpoints,
the implications of “information not registered” are dif-
ferent from those of “inappropriate treatment”.I no r d e r
to limit this problem, simple indicators derived from
data that is usually registered (treatment, patient age)
have been defined as primary and secondary endpoints,
rather than using more sophisticated ones that are
highly dependent on the quality of the register.
Maduration
The endpoints examined in the study are expected to
improve over time for various reasons: The improvements
made to the ABUCASIS electronic clinical record system
should bear fruit; the study has an open design; and the
participating doctors will experience a learning curve
throughout the study. This bias will be limited by the use
of a Control Group, and by evaluating the differences
between both groupos before evaluating any differences
observed before and after the interventions.
Surrogate endpoints
The short-term design of the evaluation will not make it
possible to assess the impact of the intervention on the
most relevant clinical endpoint (the reduction of osteo-
porotic fractures), but will be limited to the surrogate
endpoints, assuming that if the quality of the intermedi-
ate endpoints improves, the clinical endpoints will
improve as well. Although this is not a limitation of the
current study, which has been designed to measure
short-term effects, the ESOSVAL Group will design an
evaluation at five years to measure the long-term impact
of the intervention.
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